MECP2 and epilepsy: For example, although Ainhoa Pascual-Alonso and her team discovered several genes that can act as biomarkers and therapeutic targets in MECP2 duplication syndrome-induced epilepsy through RNAseq and proteomics analysis [106], there is no further evidence to prove the effectiveness of these targets in the treatment of epilepsy.